3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Squamous Cell Carcinoma of Head and Neck
5
Skin Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Lung Neoplasms
5
Carcinoma
5
Recurrence
4
Neoplasms
4
Mouth Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Vaccinia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Interventions
durvalumab
3
abemaciclib
3
Fulvestrant
3
Cisplatin
3
ribociclib
2
pembrolizumab
2
palbociclib
2
Pemetrexed
2
Nivolumab
2
Letrozole
2
Carboplatin
2
Bevacizumab
2
Anastrozole
2
130-nm albumin-bound paclitaxel
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
Sunitinib
1
STX-478
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
cemiplimab
×
90 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled